Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: Evidence of confounding by exposure characteristics

Journal of Clinical Epidemiology

Volumn 50, Issue 5, 1997, Pages 611-618

  Persson, Ingemar ^a   Bergkvist, Leif ^a   Lindgren, Christina ^a   Yuen, Jonathan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bias; Confounding; HRT; Risk factors

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; GESTAGEN;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CONTROLLED STUDY; DIETARY FIBER; EXERCISE; FEMALE; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LONG TERM CARE; NORMAL HUMAN; ORAL CONTRACEPTION; OSTEOPOROSIS; OVARIECTOMY; PARITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; SWEDEN;

AGED; CARDIOVASCULAR DISEASES; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTROGEN REPLACEMENT THERAPY; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LIFE STYLE; LOGISTIC MODELS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SELECTION BIAS; SWEDEN; TIME FACTORS;

EID: 0030925497     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(97)00004-8     Document Type: Article

References (25)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Preventive Med 1991; 20: 47-63.
2. Consensus Development Conference: Prophylaxis and treatment of osteoporosis. Am J Med 1991; 90: 107-110.
3. Ziel HK. Estrogen's role in endometrial cancer. Obstet Gynecol 1982; 60: 509-515.
4. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993; 15: 66-79.
5. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993; 15: 98-107.
6. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
7. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993; 46: 211-219.
8. Adami HO. Long-term consequences of estrogen and estrogen-progestin replacement. Cancer Causes & Control 1992; 3: 83-90.
9. Hemminki E, Sihvo S. A review of postmenopausal hormone therapy recommendations: Potential for selection bias. Obstet Gynecol 1993; 82: 1021-1028.
10. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143: 971-978.
11. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Int Med 1991; 115: 455-456.
12. Vandenbroucke JP. Postmenopausal estrogen and cardioprotection (Editorial). Lancet 1991; 337: 833-834.
13. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: Is the evidence biased? Br Med J 1994; 308: 1268-1269.
14. Grodstein F. Invited commentary: Can selection bias explain the cardiovascular benefits of estrogen replacement therapy? Am J Epidemiol 1996; 143: 979-982.
15. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199-210.
16. Persson I, Adami HO, Johansson EDB, Lindberg BS, Manell P, Westerholm B. A cohort study on estrogen treatment and risk of endometrial cancer: Evaluation of method and its applicability. Eur J Clin Pharmacol 1983; 25: 625-632.
17. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J 1989; 298: 147-151.
18. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-297.
19. Naessén T, Persson I, Adami HO, et al. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Int Med 1990; 113: 95-103.
20. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet & Gynaecol 1992; 99: 821-828.
21. Bergkvist L, Adami HO, Persson I, Schairer C. Risk factors for breast and endometrial cancer in a cohort of women treated with menopausal estrogen. Int J Epidemiol 1988; 17: 732-737.
22. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756-762.
23. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Int Med 1991; 325: 756-762.
24. Persson I, Bergkvist L, Adami HO. Reliability of women's histories of climacteric estrogen treatment assessed by prescription forms. Int J Epidemiol 1987; 16: 222-228.
25. National Pharmaceutical Company. Swedish Drug Statistics 1978-1992, yearly publication, Apoteksbolaget 1982-1992.